Athena Bioscience’s Qdolo (tramadol hydrochloride) Receives US FDA’s NDA Approval for Oral Solution

Shots:

• Athena Biosciences announced that the US FDA has approved Qdolo (tramadol hydrochloride) oral solution 5mg/1mL C-IV
• The most common AE’s (≥15.0%) observed in patients were dizziness/vertigo, nausea, constipation, headache, somnolence, vomiting, and pruritus
• Qdolo is indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It will be available at chain, independent, and specialty pharmacies
  
  Click here to­ read the full press release/ article | Ref: PRNewswire  | Image: Pharma Compass